Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
批准号:
10221341
负责人:
Galit Alter
金额:
$147.8万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-30 至 2022-08-31
关键词:
2019-nCoVAntibodiesAntibody ResponseAntibody titer measurementAutomobile DrivingCOVID-19 pandemicCessation of lifeClinicalCoronavirusDataDevelopmentDiseaseDisease OutcomeDoseEuropeHumanHumoral ImmunitiesImmuneImmunityImmunologicsIndividualInfectionInfection ControlInstitutionInterventionIsraelKineticsKnowledgeMacaca mulattaMediatingMedical centerPhasePopulationProteinsResolutionScheduleScienceSerologicalTherapeuticUnited StatesVaccinatedVaccinationVaccine Clinical TrialVaccinesantigen bindingefficacy testingfollow-upinsightneutralizing antibodynonhuman primatepreventsuccesstransmission processvaccine developmentvector-based vaccinevirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, a
critical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans.
Our preliminary data suggest that antibodies correlate with protection following vaccination in nonhuman
primates and that unique antibody functional profiles appear to predict disease outcome in natural infection in
humans. Our data also point to a converging antibody profile, including both the antigen-binding domain driving
neutralization and Fc-mediated effector functions driving protective immunity. Another gap in knowledge is the
unknown durability of protective immunity following SARS-CoV-2 infection and vaccination in humans.
Our preliminary data suggest that antibody titers may wane quickly following SARS-CoV-2 infection in humans,
but larger studies and longer follow-up are needed to define the kinetics of antibody responses in convalescent
individuals. Moreover, the durability of vaccine-elicited antibody responses remains to be determined.
We hypothesize that both convalescent and vaccinated humans will develop the functional antibody
signature that correlates with vaccine protection against SARS-CoV-2 challenge in rhesus macaques.
We further hypothesize that vaccination will induce antibodies with greater durability than those induced
by natural infection and that an immunologic correlate of durability can be defined.
Specific Aim 1. Define the antibody profiles following SARS-CoV-2 infection or vaccination that correlate
with protection. We will dissect the functional antibody responses elicited in SARS-CoV-2 infected individuals
and in SARS-CoV-2 vaccinated individuals to provide insight into correlates of protection.
Specific Aim 2. Define the immunologic correlates of durability of SARS-CoV-2 antibody responses
following infection or vaccination. We will compare the durability of antibody responses induced in SARS-
CoV-2 infected and vaccinated individuals, and we will define an immunologic correlate of durability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 Variant Testing
-
批准号:10446500
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10616544
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10203487
-
项目类别:
-
资助金额:$39.61万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10449292
-
项目类别:
-
资助金额:$40.74万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Defining humoral correlates of immunity against COVID-19
-
批准号:10265799
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2020
-
负责人:Galit Alter
-
依托单位:
Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children
-
批准号:10159844
-
项目类别:
-
资助金额:$96.06万
-
财政年份:2020
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10158451
-
项目类别:
-
资助金额:$68.97万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10402341
-
项目类别:
-
资助金额:$69.29万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10617741
-
项目类别:
-
资助金额:$62.43万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Core B
-
批准号:10339364
-
项目类别:
-
资助金额:$99.39万
-
财政年份:2018
-
负责人:Galit Alter
-
依托单位:
Killing the Reservoir with Antibodies
-
批准号:9197410
-
项目类别:
-
资助金额:$48.61万
-
财政年份:2015
-
负责人:Galit Alter
-
依托单位:
Killing the Reservoir with Antibodies
-
批准号:8656251
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2013
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8408897
-
项目类别:
-
资助金额:$60.99万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8874097
-
项目类别:
-
资助金额:$87.64万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8691723
-
项目类别:
-
资助金额:$84.27万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8496714
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
The Innate Immune Signals on B Cells that Induce ADCC Antibodies
-
批准号:8332408
-
项目类别:
-
资助金额:$43.79万
-
财政年份:2011
-
负责人:Galit Alter
-
依托单位:
The role of NK cells during acute HCV infection and antiviral therapy
-
批准号:7919782
-
项目类别:
-
资助金额:$17.12万
-
财政年份:2010
-
负责人:Galit Alter
-
依托单位:
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp
-
批准号:8072923
-
项目类别:
-
资助金额:$43.39万
-
财政年份:2010
-
负责人:Galit Alter
-
依托单位:
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp
-
批准号:7686615
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2009
-
负责人:Galit Alter
-
依托单位:
海外基金